GLP-1 Drug Dulaglutide May Reduce Kidney Scarring in Diabetes Patients
Dulaglutide showed biomarker evidence of reducing kidney fibrosis (less new scar formation, more scar breakdown) compared to insulin in type 2 diabetes patients with chronic kidney disease.
Quick Facts
What This Study Found
In this post-hoc analysis from the AWARD-7 trial, the GLP-1 agonist dulaglutide showed biomarker evidence of reducing kidney fibrosis compared to insulin glargine in type 2 diabetes patients with CKD. Specifically:
- Serum PRO-C6 (a marker of new scar tissue formation — type VI collagen) decreased with dulaglutide but increased with insulin glargine at both 26 and 52 weeks (p<0.01)
- Urine C3M (a marker of scar tissue breakdown — type III collagen degradation) increased with dulaglutide but decreased with insulin glargine (p<0.05)
This combination — less new fibrosis plus more scar tissue clearance — suggests dulaglutide may actively reverse kidney scarring, not just slow its progression. The effects were more pronounced in patients with macroalbuminuria (severe kidney damage). Both fibrosis biomarkers correlated with kidney function (eGFR), supporting their clinical relevance.
Key Numbers
N=330 analyzed · 52-week treatment · PRO-C6 (fibrosis): -4.6% dulaglutide vs +5.7% insulin (week 26, p<0.01) · C3M (scar breakdown): +10.9% dulaglutide vs -10.0% insulin (week 26, p<0.05) · Greater effects in macroalbuminuria subgroup · Both markers correlated with eGFR
How They Did This
This was an exploratory post-hoc analysis of the AWARD-7 randomized trial comparing dulaglutide 1.5 mg weekly to insulin glargine in 330 patients with type 2 diabetes and moderate-to-severe CKD. Two collagen-based fibrosis biomarkers were measured using ELISA assays: serum PRO-C6 (type VI collagen formation, reflecting new fibrosis) and urine C3M (type III collagen degradation, reflecting scar breakdown). Changes were analyzed using mixed-effects models and correlated with eGFR outcomes.
Why This Research Matters
Kidney fibrosis (scarring) is the final common pathway to kidney failure — once enough scar tissue accumulates, the kidney can't function. Until now, we could slow fibrosis but couldn't reverse it. This study provides the first biomarker evidence that a GLP-1 agonist may actually reduce kidney scarring at the molecular level, not just slow kidney function decline. If confirmed, this adds a powerful mechanistic explanation for why GLP-1 drugs protect kidneys in trials like FLOW.
The Bigger Picture
The discovery that GLP-1 agonists may have anti-fibrotic effects on the kidney adds a new dimension to their already impressive benefit profile. Combined with cardiovascular protection, weight loss, and direct kidney function preservation shown in trials like FLOW, this fibrosis mechanism helps explain why GLP-1 drugs are emerging as transformative treatments for diabetic kidney disease. Anti-fibrotic kidney therapies have been a major unmet medical need — if GLP-1 drugs fill this gap, it would represent a significant advance.
What This Study Doesn't Tell Us
This is a post-hoc exploratory analysis — the AWARD-7 trial was not designed to test kidney fibrosis as a primary outcome, so these findings are hypothesis-generating. The biomarkers are surrogate measures of fibrosis, not direct tissue measurements (which would require kidney biopsies). The comparison is against insulin glargine rather than placebo, making it unclear whether dulaglutide is reducing fibrosis or insulin is increasing it. The sample size of 330 is moderate for biomarker analyses.
Questions This Raises
- ?Would a study using kidney biopsy tissue confirm that the biomarker changes correspond to actual structural reduction in fibrosis?
- ?Do other GLP-1 agonists like semaglutide show the same anti-fibrotic biomarker changes?
- ?Is the anti-fibrotic effect a direct action of GLP-1 receptor activation on kidney cells, or an indirect result of improved glucose control and weight loss?
Trust & Context
- Key Stat:
- Fibrosis reversed, not just slowed Dulaglutide decreased new scar tissue formation (PRO-C6 down) while increasing scar breakdown (C3M up) — suggesting the GLP-1 drug may actively reverse kidney fibrosis, not just slow progression
- Evidence Grade:
- This is a post-hoc exploratory analysis from a randomized trial, using surrogate biomarkers rather than direct tissue measurement. While the biomarker changes are statistically significant and biologically coherent, the exploratory nature and lack of kidney biopsy confirmation limit the evidence grade. The findings are hypothesis-generating and require prospective validation.
- Study Age:
- Published in 2023, this analysis is recent and contributes to the rapidly evolving understanding of how GLP-1 agonists protect kidneys. The FLOW trial results published subsequently have reinforced the kidney-protective class effect.
- Original Title:
- Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide.
- Published In:
- American journal of nephrology, 54(1-2), 74-82 (2023)
- Authors:
- Tuttle, Katherine R(10), Wilson, Jonathan Matthew, Lin, Yanzhu(6), Qian, Hui-Rong, Genovese, Federica, Karsdal, Morten Asser, Duffin, Kevin L, Botros, Fady T
- Database ID:
- RPEP-07480
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs reverse kidney damage in diabetes?
This study provides early evidence suggesting they might. Biomarker analysis showed that dulaglutide (a GLP-1 agonist) reduced markers of new kidney scar tissue while increasing markers of old scar tissue being broken down — essentially, the fibrosis process appeared to be running in reverse. This is exciting because kidney scarring has traditionally been considered irreversible. However, these are biomarker findings that need to be confirmed with direct tissue examination.
What are kidney fibrosis biomarkers and why do they matter?
Kidney fibrosis (scarring) is what ultimately destroys kidney function. Biomarkers like PRO-C6 and C3M measure this process through blood and urine tests — PRO-C6 indicates new scar tissue forming, while C3M indicates old scar tissue being cleared away. Tracking these markers lets researchers assess whether a drug is affecting the underlying disease process, not just the symptoms.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07480APA
Tuttle, Katherine R; Wilson, Jonathan Matthew; Lin, Yanzhu; Qian, Hui-Rong; Genovese, Federica; Karsdal, Morten Asser; Duffin, Kevin L; Botros, Fady T. (2023). Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide.. American journal of nephrology, 54(1-2), 74-82. https://doi.org/10.1159/000529374
MLA
Tuttle, Katherine R, et al. "Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide.." American journal of nephrology, 2023. https://doi.org/10.1159/000529374
RethinkPeptides
RethinkPeptides Research Database. "Indicators of Kidney Fibrosis in Patients with Type 2 Diabet..." RPEP-07480. Retrieved from https://rethinkpeptides.com/research/tuttle-2023-indicators-of-kidney-fibrosis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.